How Bad Will the Stock Market Get?
In recent trading days, global stock markets have seen massive…
Sell
50
DERM Quote, Financials, Valuation and Earnings
Last price:
$6.12
Seasonality move
:
12.92%
Day range:
$6.23 - $7.06
52-week range:
$3.20 - $7.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.53x
P/B ratio:
8.01x
Volume:
252.3K
Avg. volume:
79.8K
1-year change:
89.13%
Market cap:
$160.8M
Revenue:
$56.1M
EPS (TTM):
-$0.74
Analysts' Opinion
-
Consensus RatingJourney Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.88, Journey Medical has an estimated upside of 41.88% from its current price of $6.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $6.96.
Fair Value
-
According to the consensus of 3 analysts, Journey Medical has 41.88% upside to fair value with a price target of $9.88 per share.
DERM vs. S&P 500
-
Over the past 5 trading days, Journey Medical has overperformed the S&P 500 by 29.75% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Journey Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Journey Medical revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Journey Medical reported revenues of $13.6M.
Earnings Growth
-
Journey Medical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Journey Medical reported earnings per share of $0.08.
Enterprise value:
165.4M
EV / Invested capital:
--
Price / LTM sales:
2.53x
EV / EBIT:
40.15x
EV / Revenue:
2.95x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-18.12x
Price / Operating cash flow:
58.24x
Enterprise value / EBITDA:
17.03x
Gross Profit (TTM):
$35.3M
Return On Assets:
-20.79%
Net Income Margin (TTM):
-26.14%
Return On Equity:
-97.05%
Return On Invested Capital:
-43.33%
Operating Margin:
-17.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $73.7M | $79.2M | $56.1M | $15.3M | $13.6M | |
| Gross Profit | $42.9M | $56.3M | $35.3M | $13M | $11.4M | |
| Operating Income | -$27.5M | $1.1M | -$18.2M | -$2.1M | -$2.3M | |
| EBITDA | -$23.2M | $1.9M | -$8.4M | -$1.2M | $3.4M | |
| Diluted EPS | -$1.68 | -$0.35 | -$0.74 | -$0.12 | $0.08 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $35.2M | $84.5M | $77.7M | $56.5M | $48.2M | |
| Total Assets | $51.9M | $97.3M | $105.2M | $76.8M | $80.2M | |
| Current Liabilities | $28.1M | $51.6M | $66.8M | $41.9M | $35.2M | |
| Total Liabilities | $41.6M | $55.2M | $88.2M | $56.5M | $60.2M | |
| Total Equity | $10.3M | $42M | $17M | $20.4M | $20.1M | |
| Total Debt | $5.2M | $812K | $22.8M | $14.6M | $24.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13.5M | $5.2M | -$9.1M | -$16.5M | $2.2M | |
| Cash From Investing | -$20M | -$5M | -$15M | -- | -$15M | |
| Cash From Financing | $16.5M | -$4.8M | $17M | $19.2M | $10.6M | |
| Free Cash Flow | -$33.5M | $240K | -$9.1M | -$16.5M | $2.2M | |
DERM
Sector
Market Cap
$160.8M
$33.3M
Price % of 52-Week High
95.47%
39.71%
Dividend Yield
0%
0%
Shareholder Yield
-6.09%
-0.91%
1-Year Price Total Return
89.13%
-47.95%
Beta (5-Year)
--
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.36
200-day SMA
Buy
Level
$5.22
Bollinger Bands (100)
Buy
Level
4.31 - 5.83
Chaikin Money Flow
Buy
Level
856.7K
20-day SMA
Buy
Level
$5.94
Relative Strength Index (RSI14)
Buy
Level
67.34
ADX Line
Buy
Level
27.76
Williams %R
Sell
Level
-16.5829
50-day SMA
Buy
Level
$5.37
MACD (12, 26)
Buy
Level
1.71
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
299.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.2505)
Sell
CA Score
(Annual)
Level (-1.9826)
Buy
Beneish M-Score
(Annual)
Level (-2.8903)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.4163)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Stock Forecast FAQ
In the current month, DERM has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DERM average analyst price target in the past 3 months is $9.88.
-
Where Will Journey Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Journey Medical share price will rise to $9.88 per share over the next 12 months.
-
What Do Analysts Say About Journey Medical?
Analysts are divided on their view about Journey Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Journey Medical is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Journey Medical's Price Target?
The price target for Journey Medical over the next 1-year time period is forecast to be $9.88 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DERM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Journey Medical is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DERM?
You can purchase shares of Journey Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Journey Medical shares.
-
What Is The Journey Medical Share Price Today?
Journey Medical was last trading at $6.12 per share. This represents the most recent stock quote for Journey Medical. Yesterday, Journey Medical closed at $6.96 per share.
-
How To Buy Journey Medical Stock Online?
In order to purchase Journey Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is JOBY Stock a Buy, Sell or Hold?
Joby Aviation (NYSE:JOBY) got started with the big idea of…
Why Did Tesla Stock Fall So Sharply?
Tesla (TSLA) stock has often gone against the grain. It…
Stock Ideas
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
20
Is AAPL Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 29x
Sell
33
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 33x
Alerts
Sell
24
FNGA alert for Apr 8
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 1.93% over the past day.
Buy
75
SOXS alert for Apr 8
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 11.22% over the past day.
Buy
82
TECS alert for Apr 8
Direxion Daily Technology Bear 3x Shares [TECS] is up 5.94% over the past day.
